HyperAcute® Pancreas Immunotherapy Clinical Trial

NewLink Genetics

Search

Main menu

Skip to primary content

Skip to secondary content

Home
About This Trial
About Pancreatic Cancer
Glossary
Selected Links
More Information

Selected Links

Thank you for your interest in the HyperAcute® Pancreas immunotherapy clinical trial. Please check this website in the weeks to come for links of interest.

About NewLink Genetics

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Our portfolio includes biologic and small-molecule product candidates intended to treat a wide range of oncology indications.

Our lead product candidate, HyperAcute Pancreas cancer immunotherapy is being studied in a Phase 3 clinical trial in surgically resected pancreatic cancer patients pursuant to an agreement with the United States Food and Drug Administration (FDA) for Special Protocol Assessment.

Copyright 2011 | NewLink Genetics